Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-06-06 Peripheral opiod-receptor antagonist
| Naldemedine tosylate Rizmoic® |
|
Formulary
|
Tablets 200 micrograms |
 LSCMMG: Naldemedine NICE TA651: Naldemedine for treating opioid-induced constipation |
|
| Naloxegol Moventig® |
|
Formulary
|
Tablets 12.5mg, 25mg |
|
LSCMMG: Naloxegol NICE TA345: Naloxegol for treating opioid‑induced constipation |
|
|
| Methylnaltrexone bromide |
|
Formulary
|
|
NICE TA277: Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) |
|
Links
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway- LSCMMG: Naldemedine
- LSCMMG: Naloxegol
- LSCMMG: Primary Care Constipation Guidelines
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA277: Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)
- NICE TA345: Naloxegol for treating opioid‑induced constipation
- NICE TA651: Naldemedine for treating opioid-induced constipation